As Rainbow Coral Corp. (OTCBB: RBCC) works to help eliminate the public health threat posed by traumatic brain injury (TBI), a new smartphone app could prove key to reducing the serious risk of concussion faced by athletes in contact sports.

Thanks in part to a $1.5 million government grant, Hockey Canada has developed a new smartphone app aimed at keeping players safe from brain injury. The app includes medically approved information on everything from concussion symptoms to return-to-play protocols, designed to help coaches, trainers and players quickly diagnose concussions suffered in the course of play and respond accordingly.

Available across all mobile platforms, the app can be updated immediately with the latest advances in TBI research, helping to keep athletes as informed on concussions as leading doctors are.

“The potential for this technology to change the way concussions are handled in sports is huge,” said RBCC CEO Patrick Brown. “Apps can be customized not only for hockey, but for football and other rough sports and deployed on sidelines and trainers’ rooms around the world instantaneously. It’s precisely the kind of technological advance that could help eliminate the risk of TBI to our athletes.”

RBCC is striving to capitalize on the growing demand for effective new treatments for TBI and other neurological health issues. The company is continuing discussions with the license holders for a NASA-developed bioreactor that assists in the expansion of adult stem cells useful in the development of potential cures. Such treatments could give RBCC access to markets in excess of $100 billion.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at www.rainbowbiosciences.com. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.